{"id":5484,"date":"2021-06-07T19:00:52","date_gmt":"2021-06-07T18:00:52","guid":{"rendered":"https:\/\/www.cilcare.com\/?p=5484"},"modified":"2023-11-14T19:11:58","modified_gmt":"2023-11-14T18:11:58","slug":"cilcare-knotus-partnership","status":"publish","type":"post","link":"https:\/\/www.cilcare.com\/jp\/2021\/06\/07\/cilcare-knotus-partnership\/","title":{"rendered":"CILcare and Knotus partner to accelerate the development of novel therapies to prevent and treat ear disorders in Korean and Asian market"},"content":{"rendered":"

Montpellier\u00a0& Seoul, June 8th, 2021:<\/strong><\/span> CILcare, the world\u2019s leading CRO dedicated to ear disorders, and Knotus, a leading Korean\u00a0non-clinical\u00a0CRO, announced today that they have entered into a strategic partnership that aims at\u00a0accelerating\u00a0the development of therapeutics\u00a0to\u00a0prevent and treat hearing disorders. CILcare and\u00a0Knotus\u00a0will be working together to\u00a0propose to\u00a0pharmaceutical, veterinary,\u00a0nutraceutical\u00a0and medical devices\u00a0industries\u00a0CILcare\u2019s\u00a0cutting-edge R&D services to support safety and efficacy evidence of their\u00a0products\u00a0on auditory functions.<\/p>\n

Hearing loss\u00a0is a\u00a0global unmet medical need\u00a0that concerns 1.5 billion people\u00a0worldwide,\u00a0with a prevalence\u00a0increasing\u00a0dramatically\u00a0stemming from\u00a0aging population, noise exposure and\u00a0auditory side-effects of multiple drugs. In 2050, 2.5 billion people will suffer from hearing loss according to the latest WHO forecasts, and the highest rise will be observed in Western\u00a0Pacific\u00a0Region.\u00a0\u00a0\u00a0<\/span>\u00a0<\/span><\/p>\n

As there\u00a0are\u00a0still no drugs on the market to treat tinnitus and hearing loss,\u00a0there is an urgent need to find effective treatment\u00a0for the sake of patients.\u00a0\u00a0<\/span><\/p>\n

\u201cKnotus\u00a0has an outstanding reputation\u00a0in the life-science\u00a0industry in Korea.\u00a0It is for CILcare an ideal partner\u00a0providing differentiated services based on veterinary expertise, experienced in various fields including\u00a0ophthalmology,\u00a0oncology,\u00a0inflammation,\u00a0and CNS\u201d,\u00a0<\/span><\/i>says Wahid Awad,\u00a0CILcare\u2019s\u00a0Chief business Officer.\u00a0<\/span>\u201cKorea is a highly dynamic market\u00a0for biopharmaceutical industry\u00a0where companies invest a significant\u00a0part of their budget in R&D to launch new drugs.\u00a0We know it is also an innovative hub for\u00a0regenerative medicines\u00a0with\u00a0abundant early adopters seeking advanced therapies.\u201d\u00a0<\/span><\/i>\u00a0<\/span><\/p>\n

\u201c<\/span>We are excited to partner with\u00a0CILcare. This\u00a0partnership brings us a rare expertise in\u00a0neurotology\u00a0which will\u00a0allow us to provide\u00a0compelling\u00a0auditory\u00a0R&D services\u00a0to\u00a0our customers\u00a0across South\u00a0Korea, China, Japan and Australia\u00a0to address\u00a0a major public health concern\u201d,\u00a0<\/span><\/i>comments\u00a0JungRae\u00a0Kim,\u00a0Overseas Sales Director<\/span>\u00a0<\/span>at\u00a0Knotus.\u00a0\u201c<\/span>Knotus\u00a0will also benefit from\u00a0CILcare\u2019s\u00a0network in animal health industry\u00a0in Europe,\u00a0thereby\u00a0strengthening its leadership\u00a0position\u00a0in pet business\u00a0and answering\u00a0growing\u00a0demand of veterinary medicines.\u201d\u00a0<\/span><\/i><\/p>\n

CILcare &\u00a0<\/span>Knotus<\/span>\u00a0partnership will be\u00a0<\/span>in the spotlight\u00a0<\/span>during BIO Korea 2021, an\u00a0<\/span>elite\u00a0<\/span>Korean convention sponsored by CILcare<\/span>,<\/span>\u00a0that connects innovative actors from the bio industry<\/span>. Bio Korea is taking place online and onsite from<\/span>\u00a0June 9<\/span><\/span>th<\/span><\/span>\u00a0<\/span>to June 11<\/span><\/span>th<\/span><\/span>\u00a02021<\/span>.<\/span><\/span><\/p>\n

About CILCARE<\/span><\/b>\u00a0<\/span>
\nCILcare is the world-leading R&D services company specialized in\u00a0hearing disorders.\u00a0Based in Montpellier, Boston, Paris,\u00a0and Copenhagen,\u00a0CILcare has become the one-stop partner for\u00a0pharmaceutical industries,\u00a0biotechs,\u00a0medtechs, veterinary & nutraceutical companies,\u00a0developing novel therapies for people with ear disorders.\u00a0<\/span>CILcare designs and performs pharmacokinetics, efficacy, and GLP ototoxicity studies to assess drugs, medical devices, cell & gene therapies,\u00a0health food ingredients,\u00a0on hearing loss, tinnitus, ototoxicity, and otitis.<\/span>\u00a0<\/span><\/p>\n

Learn more about\u00a0CILcare\u2019s\u00a0services or please contact us.<\/span>\u00a0<\/span><\/p>\n

Contact:<\/span><\/b>\u00a0Marie Peytavy-Izard, Marketing & Business Development Director<\/span>\u00a0<\/span><\/p>\n

+33769741905<\/span>\u00a0<\/span><\/p>\n

About KNOTUS<\/span><\/b><\/p>\n

Knotus\u00a0is a\u00a0leading\u00a0Korean non-clinical CRO\u00a0providing\u00a0domestic and overseas pharmaceuticals and bio ventures\u00a0services necessary for development process of medicines and health functional foods.\u00a0Knotus\u2019 mission is to\u00a0contribute to the development of bio industry with limitless research and challenging spirit with the aim of helping humankind pursue happy life.<\/span>\u00a0<\/span><\/p>\n

Contact<\/span><\/b>:\u00a0JungRae\u00a0Kim, Overseas\u00a0Sales Director<\/span>\u00a0<\/span><\/p>\n

redux0078@knotus.co.kr<\/span><\/a>\u00a0<\/span><\/p>\n

\uc774 \ubcf4\ub3c4 \uc790\ub8cc\ub97c \ud55c\uad6d\uc5b4\ub85c \uc77d\uc73c\ub824\uba74 \uc5ec\uae30\ub97c \ud074\ub9ad\ud558\uc2ed\uc2dc\uc624<\/strong><\/span><\/a><\/p>","protected":false},"excerpt":{"rendered":"

Montpellier\u00a0& Seoul, June 8th, 2021: CILcare, the world\u2019s leading CRO dedicated to ear disorders, and Knotus, a leading Korean\u00a0non-clinical\u00a0CRO, announced today that they have entered into a strategic partnership that aims at\u00a0accelerating\u00a0the development of therapeutics\u00a0to\u00a0prevent and treat hearing disorders. CILcare and\u00a0Knotus\u00a0will be working together to\u00a0propose to\u00a0pharmaceutical, veterinary,\u00a0nutraceutical\u00a0and medical devices\u00a0industries\u00a0CILcare\u2019s\u00a0cutting-edge R&D services to support safety and efficacy evidence of their\u00a0products\u00a0on auditory functions. Hearing loss\u00a0is a\u00a0global unmet medical need\u00a0that concerns 1.5 billion people\u00a0worldwide,\u00a0with a prevalence\u00a0increasing\u00a0dramatically\u00a0stemming from\u00a0aging population, noise exposure and\u00a0auditory side-effects of multiple drugs. In 2050, 2.5 billion people will suffer from hearing loss according to the latest WHO forecasts, and the highest rise will be observed in Western\u00a0Pacific\u00a0Region.\u00a0\u00a0\u00a0\u00a0 As there\u00a0are\u00a0still no […]<\/p>","protected":false},"author":3,"featured_media":5487,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5484","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-non-classe","entry","has-media"],"yoast_head":"\nCILcare and Knotus partner to accelerate the development of novel therapies to prevent and treat ear disorders in Korean and Asian market - Cilcare<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cilcare.com\/jp\/2021\/06\/07\/cilcare-knotus-partnership\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CILcare and Knotus partner to accelerate the development of novel therapies to prevent and treat ear disorders in Korean and Asian market - Cilcare\" \/>\n<meta property=\"og:description\" content=\"Montpellier\u00a0& Seoul, June 8th, 2021: CILcare, the world\u2019s leading CRO dedicated to ear disorders, and Knotus, a leading Korean\u00a0non-clinical\u00a0CRO, announced today that they have entered into a strategic partnership that aims at\u00a0accelerating\u00a0the development of therapeutics\u00a0to\u00a0prevent and treat hearing disorders. CILcare and\u00a0Knotus\u00a0will be working together to\u00a0propose to\u00a0pharmaceutical, veterinary,\u00a0nutraceutical\u00a0and medical devices\u00a0industries\u00a0CILcare\u2019s\u00a0cutting-edge R&D services to support safety and efficacy evidence of their\u00a0products\u00a0on auditory functions. Hearing loss\u00a0is a\u00a0global unmet medical need\u00a0that concerns 1.5 billion people\u00a0worldwide,\u00a0with a prevalence\u00a0increasing\u00a0dramatically\u00a0stemming from\u00a0aging population, noise exposure and\u00a0auditory side-effects of multiple drugs. In 2050, 2.5 billion people will suffer from hearing loss according to the latest WHO forecasts, and the highest rise will be observed in Western\u00a0Pacific\u00a0Region.\u00a0\u00a0\u00a0\u00a0 As there\u00a0are\u00a0still no […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cilcare.com\/jp\/2021\/06\/07\/cilcare-knotus-partnership\/\" \/>\n<meta property=\"og:site_name\" content=\"Cilcare\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-07T18:00:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-14T18:11:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2021\/06\/Illustration-PR-Knotus-partnership-v2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"CILcare\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"CILcare\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cilcare.com\/2021\/06\/07\/cilcare-knotus-partnership\/\",\"url\":\"https:\/\/www.cilcare.com\/2021\/06\/07\/cilcare-knotus-partnership\/\",\"name\":\"CILcare and Knotus partner to accelerate the development of novel therapies to prevent and treat ear disorders in Korean and Asian market - Cilcare\",\"isPartOf\":{\"@id\":\"https:\/\/www.cilcare.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cilcare.com\/2021\/06\/07\/cilcare-knotus-partnership\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cilcare.com\/2021\/06\/07\/cilcare-knotus-partnership\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2021\/06\/Illustration-PR-Knotus-partnership-v2.png\",\"datePublished\":\"2021-06-07T18:00:52+00:00\",\"dateModified\":\"2023-11-14T18:11:58+00:00\",\"author\":{\"@id\":\"https:\/\/www.cilcare.com\/#\/schema\/person\/71c4c9a5956da88e9a9de08ad23b27ac\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.cilcare.com\/2021\/06\/07\/cilcare-knotus-partnership\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cilcare.com\/2021\/06\/07\/cilcare-knotus-partnership\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\/\/www.cilcare.com\/2021\/06\/07\/cilcare-knotus-partnership\/#primaryimage\",\"url\":\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2021\/06\/Illustration-PR-Knotus-partnership-v2.png\",\"contentUrl\":\"https:\/\/www.cilcare.com\/wp-content\/uploads\/2021\/06\/Illustration-PR-Knotus-partnership-v2.png\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cilcare.com\/2021\/06\/07\/cilcare-knotus-partnership\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cilcare.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CILcare and Knotus partner to accelerate the development of novel therapies to prevent and treat ear disorders in Korean and Asian market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cilcare.com\/#website\",\"url\":\"https:\/\/www.cilcare.com\/\",\"name\":\"Cilcare\",\"description\":\"Making hearing a priority\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cilcare.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cilcare.com\/#\/schema\/person\/71c4c9a5956da88e9a9de08ad23b27ac\",\"name\":\"CILcare\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\/\/www.cilcare.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/4bc8be812ab5693ac188aed8222fa384249de7201f47b7b8db392d1474d732de?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/4bc8be812ab5693ac188aed8222fa384249de7201f47b7b8db392d1474d732de?s=96&d=mm&r=g\",\"caption\":\"CILcare\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CILcare and Knotus partner to accelerate the development of novel therapies to prevent and treat ear disorders in Korean and Asian market - Cilcare","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cilcare.com\/jp\/2021\/06\/07\/cilcare-knotus-partnership\/","og_locale":"ja_JP","og_type":"article","og_title":"CILcare and Knotus partner to accelerate the development of novel therapies to prevent and treat ear disorders in Korean and Asian market - Cilcare","og_description":"Montpellier\u00a0& Seoul, June 8th, 2021: CILcare, the world\u2019s leading CRO dedicated to ear disorders, and Knotus, a leading Korean\u00a0non-clinical\u00a0CRO, announced today that they have entered into a strategic partnership that aims at\u00a0accelerating\u00a0the development of therapeutics\u00a0to\u00a0prevent and treat hearing disorders. CILcare and\u00a0Knotus\u00a0will be working together to\u00a0propose to\u00a0pharmaceutical, veterinary,\u00a0nutraceutical\u00a0and medical devices\u00a0industries\u00a0CILcare\u2019s\u00a0cutting-edge R&D services to support safety and efficacy evidence of their\u00a0products\u00a0on auditory functions. Hearing loss\u00a0is a\u00a0global unmet medical need\u00a0that concerns 1.5 billion people\u00a0worldwide,\u00a0with a prevalence\u00a0increasing\u00a0dramatically\u00a0stemming from\u00a0aging population, noise exposure and\u00a0auditory side-effects of multiple drugs. In 2050, 2.5 billion people will suffer from hearing loss according to the latest WHO forecasts, and the highest rise will be observed in Western\u00a0Pacific\u00a0Region.\u00a0\u00a0\u00a0\u00a0 As there\u00a0are\u00a0still no […]","og_url":"https:\/\/www.cilcare.com\/jp\/2021\/06\/07\/cilcare-knotus-partnership\/","og_site_name":"Cilcare","article_published_time":"2021-06-07T18:00:52+00:00","article_modified_time":"2023-11-14T18:11:58+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/www.cilcare.com\/wp-content\/uploads\/2021\/06\/Illustration-PR-Knotus-partnership-v2.png","type":"image\/png"}],"author":"CILcare","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"CILcare","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"3\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cilcare.com\/2021\/06\/07\/cilcare-knotus-partnership\/","url":"https:\/\/www.cilcare.com\/2021\/06\/07\/cilcare-knotus-partnership\/","name":"CILcare and Knotus partner to accelerate the development of novel therapies to prevent and treat ear disorders in Korean and Asian market - Cilcare","isPartOf":{"@id":"https:\/\/www.cilcare.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cilcare.com\/2021\/06\/07\/cilcare-knotus-partnership\/#primaryimage"},"image":{"@id":"https:\/\/www.cilcare.com\/2021\/06\/07\/cilcare-knotus-partnership\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cilcare.com\/wp-content\/uploads\/2021\/06\/Illustration-PR-Knotus-partnership-v2.png","datePublished":"2021-06-07T18:00:52+00:00","dateModified":"2023-11-14T18:11:58+00:00","author":{"@id":"https:\/\/www.cilcare.com\/#\/schema\/person\/71c4c9a5956da88e9a9de08ad23b27ac"},"breadcrumb":{"@id":"https:\/\/www.cilcare.com\/2021\/06\/07\/cilcare-knotus-partnership\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cilcare.com\/2021\/06\/07\/cilcare-knotus-partnership\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/www.cilcare.com\/2021\/06\/07\/cilcare-knotus-partnership\/#primaryimage","url":"https:\/\/www.cilcare.com\/wp-content\/uploads\/2021\/06\/Illustration-PR-Knotus-partnership-v2.png","contentUrl":"https:\/\/www.cilcare.com\/wp-content\/uploads\/2021\/06\/Illustration-PR-Knotus-partnership-v2.png","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.cilcare.com\/2021\/06\/07\/cilcare-knotus-partnership\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cilcare.com\/"},{"@type":"ListItem","position":2,"name":"CILcare and Knotus partner to accelerate the development of novel therapies to prevent and treat ear disorders in Korean and Asian market"}]},{"@type":"WebSite","@id":"https:\/\/www.cilcare.com\/#website","url":"https:\/\/www.cilcare.com\/","name":"Cilcare","description":"Making hearing a priority","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cilcare.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Person","@id":"https:\/\/www.cilcare.com\/#\/schema\/person\/71c4c9a5956da88e9a9de08ad23b27ac","name":"CILcare","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/www.cilcare.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/4bc8be812ab5693ac188aed8222fa384249de7201f47b7b8db392d1474d732de?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4bc8be812ab5693ac188aed8222fa384249de7201f47b7b8db392d1474d732de?s=96&d=mm&r=g","caption":"CILcare"}}]}},"_links":{"self":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/posts\/5484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/comments?post=5484"}],"version-history":[{"count":1,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/posts\/5484\/revisions"}],"predecessor-version":[{"id":11011,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/posts\/5484\/revisions\/11011"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/media\/5487"}],"wp:attachment":[{"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/media?parent=5484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/categories?post=5484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cilcare.com\/jp\/wp-json\/wp\/v2\/tags?post=5484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}